ImageneBio | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -2.91.

EBIT: As of FY2025 Q3, the actual value is USD -26.5 M.

Segment Revenue

• License revenue for the three months ended September 30, 2025 was $0, compared to $3,500,000 for the same period in 2024. For the nine months ended September 30, 2025, license revenue was $800,000, compared to $3,500,000 in 2024.

Operational Metrics

• Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $15,558,000, compared to $3,885,000 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $25,251,000, compared to $28,350,000 in 2024.
• General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $11,036,000, compared to $1,651,000 for the same period in 2024. For the nine months ended September 30, 2025, these expenses were $15,496,000, compared to $6,008,000 in 2024.
• Net Loss: For the three months ended September 30, 2025, net loss was - $24,779,000, compared to - $3,183,000 for the same period in 2024. For the nine months ended September 30, 2025, net loss was - $38,441,000, compared to - $31,756,000 in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $40,626,000, compared to - $17,844,000 for the same period in 2024.
• Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was - $4,450,000, compared to $11,020,000 provided in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $135,468,000, compared to $0 in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue the development of IMG-007 for the treatment of atopic dermatitis and other potential indications. A Phase 2b dose-finding study was initiated in mid-2025, with topline data expected in 2027.
• Non-Core Business: The company completed the divestiture of the non-IMG-007 business related assets, business, and operations on July 25, 2025, focusing solely on the development of IMG-007.

Unique Metrics

• Stock-Based Compensation: For the nine months ended September 30, 2025, stock-based compensation expense was $15,340,000, compared to $0 in 2024.